Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.4029
0.00290.72%
Last update: Dec 18, 9:20 AM
Comments
Loading...
Cue Biopharma Analyst Ratings and Price Targets | NASDAQ:CUE | Benzinga
Cue Biopharma Inc has a consensus price target of $5.13 based on the ratings of 8 analysts. The high is $10 issued by Oppenheimer on April 9, 2024. The low is $2 issued by Citizens Capital Markets on April 2, 2025. The 3 most-recent analyst ratings were released by LUCID CAPITAL MARKETS, Citizens Capital Markets, and Stifel on August 25, 2025, April 2, 2025, and August 20, 2024, respectively. With an average price target of $3.33 between LUCID CAPITAL MARKETS, Citizens Capital Markets, and Stifel, there's an implied 706.52% upside for Cue Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
LUCID CAPITAL MARKETS
Citizens Capital Markets
Stifel
JMP Securities
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Cue Biopharma
FAQ
What is the target price for Cue Biopharma (CUE) stock?
The latest price target for Cue Biopharma (NASDAQ:CUE) was reported by LUCID CAPITAL MARKETS on August 25, 2025. The analyst firm set a price target for $4.00 expecting CUE to rise to within 12 months (a possible 892.80% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cue Biopharma (CUE)?
The latest analyst rating for Cue Biopharma (NASDAQ:CUE) was provided by LUCID CAPITAL MARKETS, and Cue Biopharma initiated their buy rating.
When was the last upgrade for Cue Biopharma (CUE)?
There is no last upgrade for Cue Biopharma
When was the last downgrade for Cue Biopharma (CUE)?
There is no last downgrade for Cue Biopharma.
When is the next analyst rating going to be posted or updated for Cue Biopharma (CUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on August 25, 2025 so you should expect the next rating to be made available sometime around August 25, 2026.
Is the Analyst Rating Cue Biopharma (CUE) correct?
While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a initiated with a price target of $0.00 to $4.00. The current price Cue Biopharma (CUE) is trading at is $0.40, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
